Page 6 - Ken Horne News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Ken horne. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Ken Horne Today - Breaking & Trending Today
Teon Therapeutics Appoints Glen Giovannetti as Independent Board Member News provided by Share this article Share this article SAN FRANCISCO, Jan. 12, 2021 /PRNewswire/ Teon Therapeutics, a private biopharmaceutical company developing a focused portfolio of small molecules that modulate metabolic signaling pathways in the tumor microenvironment, today announced the appointment of Glen Giovannetti, to its board of directors. Glen brings over 36 years of leadership success, industry expertise and board governance credentials following his retirement from EY (Ernst & Young) in December 2020. As EY s former Global Biotechnology and Life Sciences Leader, Glen has deep life sciences knowledge and financial governance, risk and reporting expertise. We are excited to have Glen joining our board, said Ken Horne, President and Chief Operating Officer of Teon Therapeutics. His experience as lead partner on numerous IPOs and M&A transactions in the biotech industry will ....
Teon Therapeutics Announces Approval for Collaboration with Cancer Research UK News provided by Share this article Share this article SAN FRANCISCO, Dec. 14, 2020 /PRNewswire/ Teon Therapeutics, a private biopharmaceutical company developing a focused portfolio of small molecules that modulate metabolic signaling pathways in the tumor microenvironment, today announced that Cancer Research UK, the world s leading cancer charity dedicated to saving lives, has formally approved Teon s TT-702 program to enter into a clinical collaboration. TT-702, a first-in-class A 2BR-specific antagonist being pursued in prostate cancer and other tumor types, expects to initiate a Phase 1b/2a clinical study in early 2021. In a collaboration, Cancer Research UK would sponsor and oversee the clinical trial, which will be run through the Centre for Drug Development. Future considerations would be contingent upon achievement of TT-702 development milestones by Teon. ....